Karuna Therapeutics, Inc. (KRTX)

NASDAQ: KRTX · IEX Real-Time Price · USD
316.24
+2.27 (0.72%)
Mar 1, 2024, 4:00 PM EST - Market closed
0.72%
Market Cap 12.06B
Revenue (ttm) 654,000
Net Income (ttm) -433.68M
Shares Out 38.15M
EPS (ttm) -11.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 242,648
Open 315.00
Previous Close 313.97
Day's Range 314.30 - 317.00
52-Week Range 158.38 - 321.45
Beta 1.19
Analysts Buy
Price Target 283.80 (-10.26%)
Earnings Date Feb 22, 2024

About KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psyc... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2019
Employees 339
Stock Exchange NASDAQ
Ticker Symbol KRTX
Full Company Profile

Financial Performance

In 2023, KRTX's revenue was $654,000, a decrease of -93.85% compared to the previous year's $10.64 million. Losses were -$433.68 million, 56.9% more than in 2022.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for KRTX stock is "Buy." The 12-month stock price forecast is $283.8, which is a decrease of -10.26% from the latest price.

Price Target
$283.8
(-10.26% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychi...

10 days ago - Business Wire

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeut...

Other symbols: BMY
18 days ago - Business Wire

Cramer names biopharma companies to watch as industry mergers start to pile up

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

2 months ago - CNBC

Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies

Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.

Other symbols: BMY
2 months ago - Invezz

Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal

Michael Yee, Jefferies Senior Biotech Analyst, joins 'Fast Money' to talk a possible boom ahead for the biotech sector.

Other symbols: BMY
2 months ago - CNBC Television

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.

NEW YORK , Dec. 22, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Karuna Therapeutics, Inc. (NASDAQ: KRTX) and its board of directors concerning the prop...

Other symbols: BMY
2 months ago - PRNewsWire

Bristol Myers Squibb to buy Karuna Therapeutics for $14 billion in cash

Stephanie Link and Jim Lebenthal join 'Halftime Report' to discuss Bristol Myers Squibb's latest announcement to buy Karuna Therapeutics for $14 billion.

Other symbols: BMY
2 months ago - CNBC Television

Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook

U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 50...

Other symbols: BMYNKE
2 months ago - Investopedia

Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal

Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.

Other symbols: BMY
2 months ago - Investopedia

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln

Dec 22 (Reuters) - Bristol Myers Squibb (BMY.N) on Friday agreed to buy Karuna Therapeutics (KRTX.O) for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as pat...

Other symbols: BMY
2 months ago - Reuters

Biotech stocks set for a rebound in 2024, analysts say

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

2 months ago - Market Watch

Bristol Myers acquiring Karuna Therapeutics in $14B deal

Bristol Myers Squibb (BMY) is buying biopharmaceutical company Karuna Therapeutics (KRTX) for $330.00 per share, with the deal valued at $14 billion. Karuna has an experimental schizophrenia drug that...

Other symbols: BMY
2 months ago - Yahoo Finance

Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers

MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Karuna (NASDAQ: KRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol-Myers. Cl...

2 months ago - PRNewsWire

Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal

Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.

Other symbols: BMY
2 months ago - CNBC

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc., and (Nasdaq: KRTX...

Other symbols: BMY
2 months ago - Business Wire

Bristol Myers to buy Karuna Therapeutics for $14B

Karuna's crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.

Other symbols: BMY
2 months ago - Fox Business

KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Karuna Therapeutics, Inc. (NASDAQ: KRTX) to Bristol Myers Squibb for $330.00 per share in...

2 months ago - Business Wire

Bristol Myers to buy Karuna Therapeutics for $14 billion

CNBC's Joe Kernen reports on the latest news.

Other symbols: BMY
2 months ago - CNBC Television

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)---- $KRTX--Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive m...

Other symbols: BMY
2 months ago - Business Wire

Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal: Report

Karuna has an experimental schizophrenia drug called KarXT up for U.S. government approval.

Other symbols: BMY
2 months ago - Barrons

Karuna Therapeutics' stock rockets into record territory after report Bristol Myers' $14 billion buyout agreement

Shares of Karuna Therapeutics Inc. KRTX, +1.80% rocketed 33.8% into record territory in premarket trading Friday, after The Wall Street Journal reported that Bristol Myers Squibb Co. BMY, +0.59% has r...

Other symbols: BMY
2 months ago - Market Watch

Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and ...

2 months ago - Business Wire

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics...

Other symbols: PRTC
3 months ago - Business Wire

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and ...

3 months ago - Business Wire

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Ph 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia.

3 months ago - Business Wire